Beyondspring INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Mar 2026

BYSI

10-K: BeyondSpring Advances Plinabulin & TPD Pipeline Amidst Financial Headwinds

BeyondSpring Inc. reported a net loss of $14.2 million for 2025, while advancing its lead asset Plinabulin in NSCLC and its SEED Therapeutics' TPD platform into clinical studies.

NASDAQ

27 Mar 2025

BYSI

Beyondspring INC

10-K: BeyondSpring Inc. Reports FY 2024 Results, Highlights Progress in NSCLC Treatment

BeyondSpring Inc. announces its FY 2024 results, emphasizing the statistically significant overall survival benefit of Plinabulin in combination with docetaxel for secondand third-line NSCLC treatment.